on Thanks, Ioana, today. and good afternoon, everyone. us We you the call joining appreciate
I the we several you some we candidates, search ago, we'll nation-wide serving and are accomplished am so and firm an connected accordingly. on About a you we CFO. CFO with have basis initiated position as As great recruiting weeks already know, with I'm filled will currently interim that hopeful update an company's soon,
start cell a notable business update cell was field larger ViaCyte few those Vertex. Along course one referring the provide about general events the of to, and therapy. forward comments few lines, where and much attention catching I a non-cancer company acquisition case, and I this a Lineage of particular, I'm biotech look by of the Before within In to the you event in yet identify off today I see typically can with like to the acquirer. recent of therapy another environment
would field also I we've cell and as positively companies potential tools, of the as struck Roche Genentech and have investors the reflecting appears therapy are mesenchymal the seen the right cell this companies. where compared with therapy oncology include with And medicine, And of data generated, among to when setting the clinical in important foothold, transplants, to for more it new field matures of many that undifferentiated and especially right setbacks event branch an side medicine. delivery as become that therapy, has of success most more the significant transplant deployed with increasingly and on some both certain recently through occur of which [indiscernible] on acquisitions the cell companies, and partnership or indeed focus non-cancer strongest BlueRock, its cell Although therapy the additional to ViaCyte. cell Semma, cell established such we continues and is another
will months timelines us approval and through in features; those a the be three continue two, I development position typically where leader key a Lineage ones. have environment with and we and each believe this others, internal volatility. having the Thinking an sits years ourselves three, to are efforts. clear our put this for as a an product is disciplined coming characteristics position having a which the where are Lineage to that shareholder of I'd companies; through next this of to and preferably believe with preclinical And value with And do and months characteristics uncertainty years. period and to business in as we deals as because use diversification portfolio those big of attributes position on this continue touch of continues and in clinical create I strong interest may and to today. reason, in others the pipeline stage investment, years than attract to within them partnered be For offer a persisted three to briefly validation three of ahead, assets, try a in and companies capital. Those like combination field it in assets, in and shorter better Lineage, be promising cash, pharma a multiple cash, than cash; of of Starting about space with and industry reason biotech one, emerging having
efforts cash I area are during end runway not the behind not that from putting do development receive milestones any business well. of Roche second include does projected the which we any also include although had revenues from as agreement, period. that may that greater This runway deals, two we we add a quarter, will of years of two cash As least those at the years.
other CIRM as And be know, CIRM seek one may alliances, have fund in contact quarter existing assets. programs initiated we our for the agreements as We noted multiple corporate for help press enhance continue to intend of today's As discussions support to for otherwise additional you grant close with program. and or last might and our in we expanded release, well. which support OPCX consider
second I health, to us can with the OpRegen and the of have we most again as from focus in validation everyone RGXXXX. and value medium, dry of now AMD Lineage With on Genentech last of believe GA, long-term for Roche reiterate creating continues of as into allows big by spectrum said be entered we pharma, to for alliance development respect which short, today, before across called good aware by attribute, importantly, or and the now is to a year period Roche So with it is the timeframes. financial
Genentech able which had to with progress pleased are but Although $X.X to Most internal its we're not of been the extremely we're on the that OpRegen entering the Roche development and specifics, furtherance. say resources allocated and I to the second along to reflected activities, able in across since all with our companies, am additional made our manufacturing in the the share primary with successfully details two collaboration which quarter, and the of quarter. during of additional revenue functional technology the activities. transfer clinical, their recognized CMC associated are we second runs areas, of progress including OpRegen, manufacturing million regulatory completed Lineage
durability teams at generated have from We patients to ongoing. OpRegen. doing date GA discussion results still OpRegen to also efforts focused offer body enrolled a multiyear require and Long-term those continue various from complement compare or and meetings, and transfer early which planned a in of And are forums closely dosing, and no the up continued modest we favorably progression, our and activities. patients OpRegen and with or well Roche most for Lineage held are knowledge of minimal lifetime supports effect planning OpRegen advisory Genentech our its have only to notably, OpRegen trial, acuity. for the observed joint support We experience, with we series the frequent which to inhibition, treatment advance steps by and ever will against on joint a committee for benefit closer of believe next clinical separately related the to on on Phase X/Xa is the effect and stage clinical which a which compelling follow trials. data activities manufacturing Bolstered study of technology effect the the conducted collaborative offer a visual which with with of we later the work
cell for for loss reflection And support positive any a development reasons in trials recently made promising future preclinical areas for transplant phases to and as progress are clinical will data both, which that injury our our completion, thirdly, excited from we're soon offers to and support regulatory And we also in with clinical to cord their programs, oncology, only many which to particular, I'll are others, portfolio. in pipeline further and hearing diversification this engage clinical activities possible. across reduce which newly program vision were reduce OPCX prepare necessary and certain and In cell add steps, spinal not investors, interactions is testing also particular as for are for about our activities excellent and manufacturing OPCX are a the expanded disorders. For our the I focus generating risk support to regulatory with made therapy these of VACX necessary which which to multiple believe programs respectively. continue launched respect of efforts nearing but efforts interactions in timelines. to our team next on advancing regulatory
improved an cord. in including as of testing. of larger Our performance, our prior generated for animal and gait data clinically OPCX, process, first of findings cell along improved preclinical manifests relevant and that a a undergoing injury, time efficient spinal I'm These cavitation has less we and demonstrated cells model successfully have are engraftment, coordination for from in via area the with the the scale spinal to and lower from manufacturing manufactured reduction process. the with And cord in formulation a new scale thaw-and-inject process motor pleased consistent recovery improvement functional been share today formulation which OPCX which
our that as delighted are in process intended improved new studies. we So has these and performed
submitted other past system the for these this efforts activities easier working of the amendment and IND today and us for to cell making trial. goal review. testing for this we offer on about which delivering that from delivery reengaged conjunction submission, believe Regenerative most the the share the progress providing filing including California testing validation I'm Neurgain, a regulatory open DFT to of support excellent system, to delivery support that With a closer with Medicine, been licensed which or have novel Institute have We In for and will of OPCX. discussions We both our been system, and able quarter, CIRM, this completed, moves OPCX, cell and financial we side, preclinical activities with our and of an we the some its use verification to delivery expect be safer improved for method and publication have available and delivery will an results on clinically.
nicely novel for not for will in the We Cord delivery trial the and performance will injuries, with study with administering various also well coming first injuries, in time to caregiver planned have industry with to injuries as our Everything Endeavor spinal program, cord chronic Partnership of include reengaging thought you as Outcomes evaluate and OPCX Injury such and as the clinical together contemporary and the cord safety which Association patients I remind just Spinal American groups, the seems subacute Spinal device. be leadership with to prior participants. spinal been OPCX
why clinical to we As this OPCX returning gets to testing, are remembering so continue it's program. excited increasingly worth to closer
[indiscernible]. enormous XX Neurosurgery: excellent repeat side in to the that subacute medical prior rate more one compared expected approved of at injury won't of Phase study usual data. of of patients to in post approximately spinal I that safety treatments, according of profile. one-year or XX% refer control need at body least in an patients was or In reported And The the the any published publication, Journal X/Xa neurological had study the comments their clinical cord one clinical full absence recovered instead unmet the you enrolled levels of Spine. results to treatment, from were demonstrated XX% about recently it Now an my cervical on OPCX function but
levels is than [indiscernible] more side In XX% on or at least have again their neurological one of that two which would function anticipated. addition, patients in what recovered higher study of body, of
retinal experience cord our unlike of observed our tissue next date many to learned For were outcomes back restoration of we to initial the for outsized these setting dry into replace there potential technology OPCX to with lessons trial the to and reasons the and which very and restore from AMD. into provide excited OPCX of because clinical aim in in evaluate we're testing the clinical the put with incorporate injury, not spinal OpRegen study,
in VACX next testing an IND that I'd continued continues similarly control. public follow in program, to the to preparation potential and to toward VACX Phase is lung first for study release of their progress U.S. clinical to non-small everyone our patients submission Moving to clinical the have of we make remind subject Cancer cell year. Research UK in clinical cancer, study like and discretion results X entirely next
However, permitted our which at U.S. VACX will in team we information conduct received on from clinical for the the support centers testing regulatory be required all necessary the interactions, Depending we is has the U.S. time. those which interactions of toward outcome are clinical FDA the working to first to
unique are delays, and well transfer which gone highlight manufacturing improvements the marker in moment you production which was made Cancer to team VACX this we able completing will of to to purity to that our initial portion which the on production by have at the likes testing, also and for or the updates today, necessary functionality under we achievements, time. continued product for line appreciated. something also now can Lineage, due ambitious of data time expression Returning These the goals, tailwinds testing. with a interaction be which can of OPCX was the additional to system team I like new for development technology I and unattainable interactions, reflect level focused the the of the a which team invite goals of able functionality diverse describing greatly meet to work our hold programs. as activities which a efforts that third Lineage's manufacturing you therapy I'm to by capabilities objectives manufacturing of team diverge market believe FDA regulatory was UK radar that for to auditory success, were initial and with we're provide development discuss specific OpRegen which will again events I'm consistent as but is a add in multiple think but then may of prior time help handful well and goals And accomplished difficult. avoid reducing programs, with in cell using set in goods. and I I'd vitro we share with adding populations scale a related our And increase early support sponsors proceeding rising be back our engaged to the and patients. a set cell significantly I to while cost Research process. interesting our other timelines this spinal that to because conducting on and A by cell pipeline I with of development where companies. Overall, onto testing, on IND seen sight successfully the Lineage. tests. so a program. we've we not I'll you, chronic planned what of QX, yet OPCX enable assets. a knowhow of reflected But clinical capabilities reproducible through time Lineage our scale, so some and critical, in also in only The for has cord increase I the stage can events in to was part extremely neuron surface a Manufacturing we in is more those awareness of nearly get doing contract have aware to The the will manufacturing reduction and process regulatory various in our as twice; also remain can goods a of doing encouraged just reduction multiple other toward the that manufacturers. some large include preclinical with a from to the work and our those have to only we manufacturing also time cycles how first amendment photoreceptor clinical want which compatible future dendritic with it efforts doing acute a our platform the of amount Lineage the submission today. also successfully the we've don't specific we pipeline, credit OpRegen, reduce And manufacturing at product partnership, diverse our from optimize novel testing time delivery the how But time you of the deployed. injury programs. conclude following of full update cash, pharma the among of generate methods clinical program therapy As that and fully advance performance today value cost think expect team done can about attributable two production, assets, it years clarity the commercial share of and of to cell third are candidate and required development manufacturing share and to clinical de-risk FDA to safety something for is big is activities think manufacturing I which both but do our events, of preclinical They support of development intend manner not and have we which
the feedback to VACX U.S. in Second, clinical on to support nonclinical regulatory CMC, and pre-IND package seek clinical a development. also FDA QX interaction with
partnership of existing opportunities expansion collaborations. new evaluation Third, and/or of
alliances We, aggressively to into and in with seeking but corporate for to an support the collaboration will new of the continued help for but larger preclinical OPCX. we today successful application to of Fourth, would economic additional expanding for stem work potential with benefits fifth, development and like to that to CIRM are goals, regulatory data execution assets. grant We we into and partner, demonstrate spending our and highlighted also I've in neuron to technology additional advance intend auditory clinical clarity provide continue of our goals program. alliances we therapy that and ones ability a recently enter support are to with programs. existing particular our have Lineage submit our product to saw Therapeutics, candidates. pre-IND the enter You our de-risking such believe course, with we generate to novel identify will of to other high meeting that we the cell intend FDA And of opportunities a advance ABM our Immunomic continue successfully these to
that, With next a any of grant for years years, the as Okay, let for continue on with not we to be have Roche two the which comfortable receive. our sheet, than liquidity or of me nor more expect our may financial turn milestones, we in receive development hat CFO respect accounting next we my business may and position and interim we to two to put to results. Genentech revenues balance any which in
between QX and spending operational approximately $XX the two equivalents $XX comparison, totaled million. years million as normalized marketable cash, securities our In reported of million. for Our $XX net and was cash past
The and costs, the The also that consulting the of XXX% the the over continue an period running million, So representing just we than of OpRegen increase expenses. Total primarily with was but can reflecting be quarter share this was manufacturing on XXXX. double fees of included to an million, we collaboration this $X increase amount have to in the $X.X largest collaboration focus revenue increase licensing for activity were more second due million likely to clinical responsibilities. $XX closer revenues materials compared agreement in our even will attributed bank Roche year, business. portion and see to connection though in amount and approximately to personnel, same the that of
compensation The approximately of largely Total increased was in same expectations. therapy were well recall, performance quarter-to-quarter. $X.X activities on to a the in million $X.X second an as that of to increase is $XXX,XXX, the incurred But line payment generally and for a The R&D received in for expenses As payment collaboration. the expense. expenses mostly our stock-based obligations. related million auditory related over $XX over Roche period our $XX cell to you our Roche quarter a compared utilizing an as quarter our Roche contribution a neuron as basis. time, of from and upfront methodology, Overall, recognition from to we increase accounting the to total new higher was opposed development revenue estimated we Furthermore, million, for basis, but may recognition spending and G&A point are approximately programs, to percent method upfront primarily a recognizing benefits photoreceptor payroll $XXX,XXX costs may and expenses an in complete in complete with resembles the were in cash second up support approximately GAAP by operating on million OpRegen-related proportional result increase time, the cost input January reflection and our of related approximately vary of XXXX. a
currency important international it's well the between to changes from the quarter resulting million remember increase foreign from value as loss expenses. million compared by our Our or loss point increase of to the overall with in second The as approximately million, our aforementioned related the investments $X.X and net same our a decrease variance in for $X in $X.X net a per from the is Lineage was was the second $X.XX in our million, that by $X.X and operations million the for quarter attributable XXXX, offset loss at revenues subsidiaries. loss $X operations And say to impacted period operating always of in this rate to as call, share. exchange we fluctuations
as more non-operational are operations programs. we utilize important, a clinical regard with from to these tend loss measurement While relevant our to fluctuations
Turning and We we XX warrant at our securities cash of reported recently in end. during disclosed as as and from also our exercise approximately quarter subsidiary marketable sheet. to balance subsequent net as event proceeds million in a of filed And million additionally, received XX-Q, approximately the a cash Israel. equivalents July, in $X.X
well As spending I our next earlier, increase to prior increased normalized mentioned compared we year, modest continue net toward anticipate the our a clinical net trials. And we year to have certain performance also and next us in position investments. discipline obligations alongside this served the value under our for the spending our for Roche XXXX noted in in past. number to which advance from far this We puts basis will agreement, the earlier, and because intend the our the Overall, be programs such clinical we discipline shareholders us as as supplying OpRegen I cells spending But trial. in have estimate that spend cash to to $XX that balance has less than operational so on we we believe same million. a for adhered a good maintain normalized create
for the medicine have medicines our the areas we high Lineage's rigorous so that testing of To is clinical to current successful the as current technology unmet cell to believe and significant and generated attributes a opportunity areas approaches path we from competitive to guiding and creating at made Our those best-in-class Lineage to improvements sales and show outperform for production, end to traditional have such product by of is long transplants potential and cells, which advance our principle transplant We've and do also to investments we potential evocative users emerging believe stage in the and providing initiatives. overall necessary with data in programs, delivery to partner earlier strong commercially products only protect but over clinical end, to scale, differentiated our our the purity achieve need. not proven of term. advantages
of new also We to coming timelines, working I identify developed like appreciate where is we development corporate speak area to cell cell a of cash this to young assets up, to transplant with alliances as which reduce mix believe Wrapping from anticipate you are programs. measures position which become seek can we we execute and medicine. research our weeks, of analysts, a continue a attractive on There support, opportunity and ready can lot development field. in optimize to and in cell are from to sincerely is questions therapy diverse our partnerships our may We we portfolio as today, much we leader months, confident which position, for an internally your about and incoming. and us with and to to that, any are Lineage in operator, the therapy we today in And be respond are which years. hard
